Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
34. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
35. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
36. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
37. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
38. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
39. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
40. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
42. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
43. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
44. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
45. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
46. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
47. Cow’s milk allergy: the future
- Dr. Carina Venter
-
48. Cow's milk allergy: management
- Dr. Carina Venter
-
49. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
50. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
51. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
52. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
53. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
54. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
55. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
56. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
57. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
58. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
60. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
61. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
62. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
63. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
64. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
65. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
66. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
67. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
68. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
69. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
70. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
71. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
72. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
73. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
74. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
75. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
76. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
77. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
78. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
79. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
80. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
81. AI and big data in drug discovery
- Mr. Ed Addison
-
82. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
83. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
84. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
85. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
86. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
87. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
88. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
89. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
90. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
91. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
92. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
93. New drugs for asthma
- Prof. Peter Barnes
-
94. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
95. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Topics
- Topic 1: neurogenic Orthostatic Hypotension
- Orthostatic Hypotension in PD
- Correlates of OH in PD
- In PD, OH greatly increases risk of falls
- In PD, OH increases cognitive impairment
- In PD, OH impairs quality of life
- Fatigue associated with cardiac sympathetic lesion
- OH is associated with supine hypertension
- In PD, OH worsens survival
- No effect of levodopa treatment
- Take-home #1
- Algorithmic approach to OH
- Neurogenic Orthostatic Hypotension
- Valsalva BP and HR: normal
- Baroreflex-sympathoneural and cardiovagal failure
- Primary' CAF syndromes are synucleinopathies
- Valsalva BP in nOH syndromes
- Take-home #2
- Topic 2: the heart of PD
- Cardiac sympathetic neuroimaging in synucleinopathies
- Myocardial catecholamine deficiency in PD
- Profound myocardial NE deficiency in PD
- 18F-DA PET in synucleinopathies
- Post-mortem validation of 18F-DA PET
- An apparent paradox
- The 'sick-but-not-dead' concept
- Treatment implications - main points
- Treatment implications
- Decreased vesicular uptake indexes in LBDs
- Accelerated 18F loss & decreased vesicular storage
- Vesicular storage defect due to synucleinopathy
- 18F-DA & 11C-MRB PET to assess vesicular storage
- Decreased vesicular storage in PD+OH
- Decreased vesicular storage in PD
- Topic 3: future trends
- 18F-DA PET separates PD+OH from MSA-P
- Tri-phasic loss of cardiac NE and putamen DA
- Cardioselective sympathetic noradrenergic lesion (1)
- Cardioselective sympathetic noradrenergic lesion (2)
- Phenoconversion of PAF to PD+OH or DLB
- LB PAF entails central LBD
- PAF evolving to DLB and pre-terminal PD
- SNS ganglion in PAF evolving to DLB and pre-terminal PD
- SNS alpha-synuclein in PAF evolving to DLB
- Three SNS - innervated skin constituents
- Intra-neuronal alpha-synuclein and vesicular storage defect in LB nOH
- Post-mortem alpha-synuclein and THir in PD
- Post-mortem skin SMG, cardiac aS and NE in PD
- Take-home #3
- Principles of management
- Education (1)
- Education (2)
- Elevate the head of the bed
- The osmopressor response
- Drug treatment
- Midodrine and phenylephrine
- L-DOPS and L-DOPA
- Take-home #4
- The intramural NINDS PDRisk study
- Low 18F-DA predicts central LBDs
- Body-first' progression
- Model predictions about treatment effects
- Take-home #5
- Conclusions
- Acknowledgements
Topics Covered
- Neurogenic orthostatic hypotension in Parkinson’s Disease
- Baroreflex-sympathoneural and cardiovagal failure
- Differentiation of PD+OH from MSA-P
- ‘Sick-but-not-dead’ phenomenon
- Alpha-synucleinopathy
- Causes of cardiac noradrenergic deficiency
- Sympathetic denervation
- Using cardiac sympathetic neuroimaging for identifying central LBDs early
- Future trends
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Goldstein, D.S. (2023, September 28). Cardiovascular involvement in Parkinson’s disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 1, 2024, from https://doi.org/10.69645/LQUX6575.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. David S. Goldstein has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello everyone. I'm
Dave Goldstein.
I'm the Chief of the
Autonomic Medicine Section
in the Division of
Intramural Research at
the National Institute of
Neurological
Disorders and Stroke
at the National Institutes
of Health in Bethesda,
Maryland, in the USA.
Today, I'm going
to be lecturing on
cardiovascular involvement
in Parkinson's disease.
0:28
There are three general
topics for today's lecture.
One is on neurogenic
orthostatic hypotension,
a characteristic feature of
Parkinson's with
autonomic failure.
Then, I'm going to go into
the sympathetic
innervation of the heart,
which plays a major role in
the cardiovascular abnormalities
that are found in Parkinson's.
Then, I'll finish with
future trends as I see
them in this area.
1:01
Two general areas under
neurogenic orthostatic hypotension
that I'll be covering.
One is on the clinical and
prognostic significance
and the second is on how you
identify orthostatic
hypotension as neurogenic.
Concerning orthostatic
hypotension.
1:18
The frequency of orthostatic
hypotension and
Parkinson's varies
remarkably among studies.
This is because of
different referral patterns
to different types of centers.
For instance, a neurology center
will see the movement
disorder and
may underestimate
the frequency of
orthostatic hypotension
because of dependence
on complaints.
Many patients with Parkinson's
orthostatic hypotension
don't have any symptoms of
orthostatic hypotension.
Orthostatic hypotension
in Parkinson's can be
an early finding
in this situation
and can be misdiagnosed as
multiple system atrophy or
pure autonomic failure.
We'll be going over some of
the clinical correlates
that are related
to the treatment considerations
for Parkinson's with
orthostatic hypotension.
I'll provide evidence that
orthostatic hypotension in
Parkinson's Disease occurs
independently of
Levodopa treatment.
However, dopaminergic
drugs such as
Levodopa decrease blood pressure
when the person is standing.
Orthostatic hypotension
in Parkinson's
is often associated with
supine hypertension and this
poses a treatment dilemma.
Some of the special
treatment considerations
that we'll be reviewing are
that orthostatic hypotension in
Parkinson's usually is
worse in the morning.
It's associated with heat
intolerance, post-exercise,
drop in blood pressure,
and post-prandial hypotension
after eating a large meal.
Acute water ingestion can
raise the blood pressure,
and this provides a useful
tact as we'll get into it.
Finally, I'll discuss
the importance
of determining whether
the patient has
denervation super sensitivity
because this would drive
the choice of drug used
to treat orthostatic
hypotension.